Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Net: 2011-2024

Historic Receivables - Net for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Dec 2024 value amounting to $638,000.

  • Lineage Cell Therapeutics' Receivables - Net fell 68.64% to $127,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $127,000, marking a year-over-year decrease of 68.64%. This contributed to the annual value of $638,000 for FY2024, which is 14.36% down from last year.
  • Lineage Cell Therapeutics' Receivables - Net amounted to $638,000 in FY2024, which was down 14.36% from $745,000 recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables - Net peaked at $50.8 million during FY2021, and registered a low of $242,000 during FY2020.
  • Moreover, its 3-year median value for Receivables - Net was $638,000 (2024), whereas its average is $561,000.
  • In the last 5 years, Lineage Cell Therapeutics' Receivables - Net surged by 20,908.26% in 2021 and then tumbled by 99.41% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Receivables - Net stood at $242,000 in 2020, then soared by 20,908.26% to $50.8 million in 2021, then plummeted by 99.41% to $300,000 in 2022, then surged by 148.33% to $745,000 in 2023, then fell by 14.36% to $638,000 in 2024.